Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Henan Taloph Pharmaceutical Stock Co Ltd to Acquire 51% of Xingtai-based Pharmaceutical Company


Thursday, 18 Jul 2013 08:00pm EDT 

Henan Taloph Pharmaceutical Stock Co Ltd announced that the Company has decided to acquire a 51% stake in a Xingtai-based pharmaceutical company (Company A), which is engaged in the wholesale of Chinese herbal medicine, chemical medicine preparation, antibiotics, biochemical drugs and biological products, for RMB 841,500, together with Wang Xianting and Luo Jianchao, who will acquire the remaining 45% and a 4% stake for RMB 742,500 and RMB 66,000, from Wu Guicun, Ma Yuexiang and Wu Guohua. After the acquisition, the three new shareholder will inject capital into Company A, to increase Company A's registered capital from RMB 1 million to RMB 10 million. 

Company Quote